Clinical trials
BCLC Stage C Hepatocellular Carcinoma clinical trials
Below are recruiting bclc stage c hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 116 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06323382Recruiting
Liver cancer: local therapy plus immunotherapy combo
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
Beijing, Beijing MunicipalityAges 18–80 - NCT06530251RecruitingPhase 1/Phase 2
AK112 for advanced liver cancer (HCC)
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
Beijing, Beijing MunicipalityAges 18–75 - NCT06485466RecruitingPhase 3
TACE plus Camrelizumab and Apatinib for liver cancer that can't be removed by surgery
This trial tests combining a liver-directed treatment (TACE) with two medications (Camrelizumab and Apatinib) to see if it works better for people with liver cancer that cannot be surgically removed. It is for people who have not had any previous treatment for their cancer.
Chengdu, SichuanAges 18–80 - NCT05911633Recruiting
Doxorubicin beads for liver cancer that cannot be cut out
This trial tests BioPearl™ “microspheres” loaded with doxorubicin, delivered to the liver, for people with unresectable hepatocellular carcinoma (HCC). It may help shrink or control liver tumors when surgery or curative treatment isn’t possible.
BrusselsAges 18 years+ - NCT07088081Enrolling by invitation
Immunotherapy drugs for advanced liver cancer
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
Cairo, AbbasyaAges 18 years+ - NCT06478927Recruiting
Palbociclib for advanced liver cancer after other treatments
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
Zhengzhou, HenanAges 18–75 - NCT05844046RecruitingPhase 2
Triple drug treatment for advanced liver cancer that can’t be removed
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
MunichAges 18 years+ - NCT07479485RecruitingPhase 1/Phase 2
MRG006A combo for advanced liver cancer
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07064681Recruiting
AK104 plus TACE for resectable liver cancer
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06427941RecruitingPhase 1/Phase 2
Study of BGB-B2033 with other drugs for advanced solid tumors
This study tests a new drug called BGB-B2033, alone or with other drugs (tislelizumab and bevacizumab), in people with certain advanced cancers. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
Birmingham, AlabamaAges 18 years+ - NCT07062055RecruitingPhase 2
Combination therapy for advanced liver cancer that has spread
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
Jinan, ShandongAges 18–70 - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other tumors with specific genetic changes
This trial tests a new pill, TYRA-430, for people with advanced liver cancer (hepatocellular carcinoma) or other solid tumors that have certain genetic changes (in the FGF/FGFR pathways). It aims to see if the drug is safe and if it can shrink or slow the growth of the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT06796803RecruitingPhase 2/Phase 3
Combination therapy before surgery for liver cancer
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Harbin, HeilongjiangAges 18–75 - NCT07557251RecruitingPhase 1
Combination immunotherapy for advanced liver cancer with hepatitis B
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
BeijingAges 18–70 - NCT07303712Recruiting
Liquid Biopsy for Liver Cancer After Y90 Treatment
This study uses a simple blood test (called a liquid biopsy) to learn more about your liver cancer after you receive a targeted radiation treatment called Y90 radioembolization. The goal is to see if the blood test can help doctors better understand how the cancer responds to treatment.
Palo Alto, CaliforniaAges 18 years+ - NCT03899428RecruitingPhase 2
Immune therapy versus targeted therapy for advanced liver cancer
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hong Kong, Hong Kong SARAges 18 years+ - NCT06537908Recruiting
Check if a new drug combo works for advanced liver cancer
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
ShanghaiAges 18–90 - NCT05738616RecruitingPhase 3
Testing lenvatinib plus TACE and immunotherapy before liver surgery
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
Chengdu, SichuanAges 18–75 - NCT07490262RecruitingPhase 2/Phase 3
Immunotherapy combo for advanced liver cancer as first treatment
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hefei, AnhuiAges 18–75 - NCT06605664RecruitingPhase 2
New MRI scan for liver cancer with radiation and immunotherapy
This trial tests a new type of MRI scan (hyperpolarized 13C-MRI) in people with liver cancer who are already receiving radiation therapy, atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy). The goal is to see if the scan can help doctors better understand how the cancer responds to treatment.
Taoyuan City, TaiwanAges 18 years+ - NCT07483359RecruitingPhase 2
Combination therapy for advanced liver cancer with portal vein tumor thrombus
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
Shenyang, LiaoningAges 18–80 - NCT07100405Recruiting
TACE plus Immunotherapy for Advanced Liver Cancer
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06526104RecruitingPhase 2
Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
San Antonio, TexasAges 18 years+
Hear when a new BCLC Stage C Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bclc stage c hepatocellular carcinoma?
- Yes. Clin2 currently lists 116 recruiting bclc stage c hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bclc stage c hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bclc stage c hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- BCLC Stage B Hepatocellular Carcinoma
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8
- Stage IIIA Hepatocellular Carcinoma AJCC v8
- Stage IIIB Hepatocellular Carcinoma AJCC v8
- Hepatocellular Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.